La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Pharmaniaga Berhad Dividendo

Dividendo criteri di controllo 0/6

Pharmaniaga Berhad al momento non paga dividendi.

Informazioni chiave

Rendimento del dividendo

Rapporto di remunerazione

Rendimento medio del settore	1.6%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	RM 0.093
Utile per azione	-RM 0.039
Previsione del rendimento del dividendo	0%

Aggiornamenti recenti sui dividendi

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

May 28

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di PHARMA siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di PHARMA siano aumentati.

Rendimento dei dividendi rispetto al mercato

Pharmaniaga Berhad Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di PHARMA rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (PHARMA)	0%
Fondo del 25% del mercato (MY)	1.9%
Top 25% del mercato (MY)	4.7%
Media del settore (Healthcare)	1.6%
Analista previsionale (PHARMA) (fino a 3 anni)	0%

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di PHARMA rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di PHARMA rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: PHARMA non sta pagando un dividendo degno di nota per il mercato MY.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché PHARMA non ha segnalato alcun pagamento.

Pharmaniaga Berhad Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Upcoming dividend of RM0.05 per share

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Upcoming dividend of RM0.02 per share

Recent updates

Pharmaniaga Berhad Announces Redesignation of Encik Zulkifli Bin Jafar from Executive Director to Managing Director, Effective September 1, 2024

Second quarter 2024 earnings released

High number of new directors

New minor risk - Share price stability

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Now 20% overvalued after recent price rise

First quarter 2024 earnings released: EPS: RM0.018 (vs RM0.002 in 1Q 2023)

Now 24% undervalued after recent price drop

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad, Annual General Meeting, Jun 05, 2024

High number of new directors

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Member of Audit Committee

Pharmaniaga Berhad Announces the Retirement of Encik Mohamed Iqbal Abdul Rahman as Chief Operating Officer

New major risk - Revenue and earnings growth

Full year 2023 earnings released: RM0.057 loss per share (vs RM0.46 loss in FY 2022)

Pharmaniaga Berhad Appoints Tuan Drs. Imam Fathorrahman as Independent and Non Executive Director, Effective March 1, 2024

Pharmaniaga Berhad Appoints Dato' Dr Faridah Aryani Binti Md Yusof, as Independent and Non Executive Director Effective March 1, 2024

Pharmaniaga Berhad Announces Resignation of Puan Dayana Rogayah Binti Omar as Non Independent and Non Executive Alternate Director

New minor risk - Share price stability

Third quarter 2023 earnings released: RM0.037 loss per share (vs RM0.007 profit in 3Q 2022)

Price target decreased by 19% to RM0.28

High number of new and inexperienced directors

Second quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 2Q 2022)

Pharmaniaga Berhad Announces Appointment of Encik Ahmad Shahredzuan Mohd Shariff as Non Independent and Non Executive Member of Risk Committee

New minor risk - Shareholder dilution

New minor risk - Market cap size

Pharmaniaga Berhad announced that it expects to receive MYR 44.20988 million in funding

Pharmaniaga Berhad Announces the Retirement of Dr Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.021 in 1Q 2022)

Pharmaniaga Berhad Announces the Resignation of Datuk Dr Azhar Ahmad as Independent and Non Executive Director

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Full year 2022 earnings released: RM0.46 loss per share (vs RM0.13 profit in FY 2021)

Price target decreased by 33% to RM0.41

Pharmaniaga Berhad Announces Resignation of Najmil Faiz Mohamed Aris as Independent and Non Executive Member of Nomination and Remuneration Committee

Third quarter 2022 earnings released: EPS: RM0.007 (vs RM0.038 in 3Q 2021)

Pharmaniaga Berhad Declares Third Interim Dividend for the Third Quarter Ended 30 September 2022, payable on 22 February 2023

High number of new directors

Pharmaniaga Berhad (KLSE:PHARMA) entered into a Memorandum of Understanding to acquire JDMAS Commerce Sdn Bhd.

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Consensus EPS estimates fall by 13%

Price target decreased to RM0.75

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0.01 in 2Q 2021)

Pharmaniaga Berhad Announces Second Interim Dividend for the Year Ended December 31, 2022, Payable on October 04, 2022

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Member of Risk Committee

Pharmaniaga Berhad Appoints Mary Jane Cardosa as Independent and Non Executive Director

Pharmaniaga Berhad Appoints Datuk Lim Thean Shiang as Independent and Non Executive Director

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Price target decreased to RM0.87

Pharmaniaga Berhad Declares First Interim Dividend for the Financial Year Ending 31 December 2022, Payable on 06 July 2022

Pharmaniaga Berhad Appoints Abdul Razak Bin Ahmad as Independent and Non-Executive Member of Risk Committee

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Pharmaniaga Berhad, Annual General Meeting, Jun 13, 2022

High number of new and inexperienced directors

Upcoming dividend of RM0.05 per share

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Pharmaniaga Berhad Declares Fourth Interim Dividend for the Financial Year Ending 31 December 2021, Payable on 05 April 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pharmaniaga Berhad Announces Re-Designation of Encik Zulkifli Jafar, Independent Director as Executive Director

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Consensus EPS estimates increase to RM0.09

Upcoming dividend of RM0.02 per share

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Third quarter 2021 earnings released: EPS RM0.038 (vs RM0.001 in 3Q 2020)

Upcoming dividend of RM0.015 per share

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Independent Non-Executive Director Zainal Shariff has left the company

Second quarter 2021 earnings released: EPS RM0.011 (vs RM0.008 in 2Q 2020)

Pharmaniaga Berhad (KLSE:PHARMA) Has A Somewhat Strained Balance Sheet

Investor sentiment improved over the past week